E van Werkhoven
Overview
Explore the profile of E van Werkhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
IJzerman N, van Werkhoven E, Mohammadi M, Hollander D, Bleckman R, Reyners A, et al.
ESMO Open
. 2022 Dec;
7(6):100649.
PMID: 36493601
Background: Sex differences in cancer have gained attention in recent years. The role of sex as a prognostic factor in gastrointestinal stromal tumours (GIST) has not been well established. The...
2.
Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman J, Frodin J, et al.
ESMO Open
. 2022 Jul;
7(3):100427.
PMID: 35798468
Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding...
3.
van Berge Henegouwen J, Jebbink M, Hoes L, van der Wijngaart H, Zeverijn L, van der Velden D, et al.
Eur J Cancer
. 2022 Jun;
171:114-123.
PMID: 35716537
Introduction: In 1-3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no HER2-targeted treatment is approved for NSCLC....
4.
van der Noordaa M, van Duijnhoven F, Cuijpers F, van Werkhoven E, Wiersma T, Elkhuizen P, et al.
Br J Surg
. 2021 Jun;
108(6):667-674.
PMID: 34157085
Background: The nodal positivity rate after neoadjuvant chemotherapy (ypN+) in patients with clinically node-negative (cN0) breast cancer is low, especially in those with a pathological complete response of the breast....
5.
Ooft S, Weeber F, Schipper L, Dijkstra K, McLean C, Kaing S, et al.
ESMO Open
. 2021 Apr;
6(3):100103.
PMID: 33887686
Background: Organoid technology has recently emerged as a powerful tool to assess drug sensitivity of individual patient tumors in vitro. Organoids may therefore represent a new avenue for precision medicine,...
6.
Raphael Daniela D, Russell N, van Werkhoven E, Immink J, Westhoff D, Stenfert Kroese M, et al.
Breast Cancer Res Treat
. 2020 Oct;
185(3):685-695.
PMID: 33099691
Purpose: Patient decision aids (PtDAs) have been reported to have a positive influence on patients making a health care decision in trials. Nevertheless, post-trial implementation is poor. The aim of...
7.
Frijstein M, Lok C, van Trommel N, Ten Kate-Booij M, Massuger L, van Werkhoven E, et al.
BJOG
. 2019 Dec;
127(3):389-395.
PMID: 31794098
Objective: Presence of lung metastases in low-risk gestational trophoblastic neoplasia (GTN) is generally considered not to influence prognosis. However, in a recent study in the Netherlands, GTN patients with lung...
8.
van der Velden D, Hoes L, van der Wijngaart H, van Berge Henegouwen J, van Werkhoven E, Roepman P, et al.
Nature
. 2019 Oct;
574(7776):127-131.
PMID: 31570881
The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available. However, when patients with such variants are treated with drugs outside...
9.
de Haan R, van Werkhoven E, van den Heuvel M, Peulen H, Sonke G, Elkhuizen P, et al.
BMC Cancer
. 2019 Sep;
19(1):901.
PMID: 31500595
Background: Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. Olaparib is a PARP inhibitor with a favourable safety...
10.
van Waalwijk van Doorn-Khosrovani S, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, et al.
Ann Oncol
. 2019 May;
30(5):663-665.
PMID: 31038154
No abstract available.